Archives

The WHO published the Global TB Report 2023. This report provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the [...]

We would like to share the (draft) program for the TBVI symposium 2024, which will be held on January 30 and 31, 2024 in Les Diablerets. Register here  for the TBVI symposium 2024    TBVI [...]

Would you like to present your work at the TBVI Annual Symposium? To encourage talented young scientists and recognise outstanding contributions to TB vaccine research and development, TBVI [...]

Diversification of the vaccine development pipeline has been identified as a priority area in the Global TB Vaccine R&D Roadmap. The TBVAC-HORIZON consortium has been able to secure funds for [...]

The TuBerculosis Vaccine Initiative (TBVI) Governance Board would like to announce a vacancy for the Executive Director of the organization. The Board has launched the search for a new Director [...]

TBVI Governance Board Communiqué Tuberculosis (TB) is a major unsolved global health problem. Novel vaccines against TB will be critical tools to ultimately end this silent pandemic. TBVI and its [...]

From 15-18 May 2023, the first annual progress meeting of the MTBVAC phase III clinical trial EDCTP co-funded project took place in Andasibe and Antananarivo, Madagascar. The consortium, composed [...]

The Horizon Europe programme has funded the ITHEMYC project to establish a critical path for selection of promising innovative adjunct TB immunotherapies and progress 2 of these immunotherapies [...]

The Horizon Europe programme has funded the TBVAC-HORIZON project to improve the understanding of lung immunity to tuberculosis infection and to establish a diversified innovative TB vaccine [...]

The four EDCTP-funded late-stage TB vaccine development projects: POR TB Consortium, priMe and MTBVAC-Newborns Phase 2a and MTBVACN3, meet on a regular basis to exchange knowledge and [...]